All ACS (including AMI): 4 trials - APPRAISE 2 - APPRAISE-1 (10mg od) - APPRAISE-1 (2.5 mg bid) - APPRAISE japan
All type of patients: 4 trials - APPRAISE 2 - APPRAISE-1 (10mg od) - APPRAISE-1 (2.5 mg bid) - APPRAISE japan
Patients with a recent ACS: 4 trials - APPRAISE 2 - APPRAISE-1 (10mg od) - APPRAISE-1 (2.5 mg bid) - APPRAISE japan
All type of patients : 3 trials - ARISTOTLE - AVERROES - phase 2 apixaban
Patients ineligible for warfarin: 1 trials - AVERROES
Primary prevention of thromboembolic events: 3 trials - ARISTOTLE - AVERROES - phase 2 apixaban
3 trials - AMPLIFY - AMPLIFY-EXT 2.5mg - AMPLIFY-EXT 5mg
elective major knee surgery : 3 trials - ADVANCE 2 - ADVANCE-1 - APROPOS 2.5mg
All type of patients : 4 trials - ADVANCE 2 - ADVANCE 3 - ADVANCE-1 - APROPOS 2.5mg
Elective hip replacement: 1 trials - ADVANCE 3
Elective major knee surgery : 2 trials - ADVANCE 2 - APROPOS 2.5mg
Medical patients: 1 trials - ADOPT
Orthopaedic surgery: 4 trials - ADVANCE 2 - ADVANCE 3 - ADVANCE-1 - APROPOS 2.5mg
Orthopedic surgery : 4 trials - ADVANCE 2 - ADVANCE 3 - ADVANCE-1 - APROPOS 2.5mg
Patients with cancer: 1 trials - CV185-027
secondary prevention of VTE : 2 trials - AMPLIFY-EXT 2.5mg - AMPLIFY-EXT 5mg
All type of patients: 4 trials - AMPLIFY - AMPLIFY-EXT 2.5mg - AMPLIFY-EXT 5mg - Botticelli DVT
All types of patients: 4 trials - AMPLIFY - AMPLIFY-EXT 2.5mg - AMPLIFY-EXT 5mg - Botticelli DVT
Patients with cancer: 2 trials - CAP - CARAVAGGIO